network meta-analysis of randomized controlled trials is increasingly used to combine both direct evidence comparing treatments within trials and indirect evidence comparing treatments across different trials. When the outcome is binary, the commonly used contrast-based network meta-analysis methods focus on relative treatment effects such as odds ratios comparing two treatments. as shown in a recent report, when using contrast-based network metaanalysis, the impact of excluding a treatment in the network can be substantial, suggesting a methodological limitation. in addition, relative treatment effects are sometimes not sufficient for patients to make decisions. For example, it can be challenging for patients to trade off efficacy and safety for two drugs if they only know the relative effects, not the absolute effects. a recently proposed arm-based network meta-analysis, based on a missing-data framework, provides an alternative approach. it focuses on estimating population-averaged treatment-specific absolute effects. this article examines the influence of treatment exclusion empirically using 14 published network meta-analyses, for both arm-and contrast-based approaches. the difference between these two approaches is substantial, and it is almost entirely due to single-arm trials. When a treatment is removed from a contrast-based network meta-analysis, it is necessary to exclude other treatments in two-arm studies that investigated the excluded treatment; such exclusions are not necessary in arm-based network meta-analysis, leading to substantial gain in performance. (Epidemiology 2016;27: 562-569) C omparative effectiveness research is aimed at informing health care decisions concerning the benefits and risks of different diagnostic and intervention options. the growing number of treatment options for a given condition, as well as the rapid a the weighted degrees refer to the corresponding full network. b rank from largest to smallest according to the weighted degrees within the corresponding network. c rank from smallest to largest according to the weighted degrees within the corresponding network. d in each of these three networks, one particular treatment is not removed to remain network connectivity (tables 1 and 2).
escalation in their cost, has created a greater need for rigorous comparisons of multiple treatments in clinical practice. to simultaneously compare multiple treatments for a given condition, network meta-analysis methods have recently been developed, expanding the scope of conventional pairwise meta-analysis. network meta-analysis simultaneously synthesizes both direct comparisons of interventions within randomized controlled trials (rcts) and indirect comparisons across rcts [1] [2] [3] [4] [5] [6] . currently, much effort in network meta-analysis has been devoted to contrast-based approaches, which focus on investigating relative treatment effects, such as odds ratios (Ors), when the outcome is binary. However, population-averaged absolute risks may be preferred in some situations such as cost-effectiveness analysis 7, 8 . in addition, relative treatment effects are sometimes insufficient for patients to make decisions. For instance, consider a patient's choice between treatments a and B with the following two sets of 1-year survival rates: (1) π A = 0 8
. versus π B = 0 5 . ; (ii) π A = 0 004 . versus π B = 0 001 . . Most likely, patients will strongly prefer treatment a in scenario (1) but have little preference in scenario (2) , yet both have Or 4.0.
contrast-based network meta-analysis can backtransform Ors to population-averaged absolute risks only if the absolute risk of a given reference treatment group can be accurately estimated from external data, or can be estimated using a separate model to analyze responses for the reference arm from the network 7, 8 . Both approaches depend on strong assumptions. For the approach using external data, even if such external data are available, they may come from a population different from the one represented in the network metaanalysis, and the assumption of transitivity of relative effects on the Or scale (i.e., that treatment effects are independent of baseline risks) is rather strong. the choice of the Or scale is generally arbitrary or conventional, and there is no particular reason to expect effects in different trials to be exchangeable on the Or scale. For the approach using a distinct model for the reference arm, under the theory of missing data, this analysis is unbiased only under a strong assumption of missing completely at random, i.e., that each study randomly chooses which treatment arms to include. in addition, if the estimation of absolute effects uses a subset of the same trials used for the estimation of relative effects, then the estimated absolute and relative effects are not independent. thus, one would need to model the correlations among the two sets of estimates, which is not straightforward. Finally, the back-transformed relative risks and risk differences can be noticeably different depending on which treatment is chosen as the reference group, even with exactly the same model and priors (eappendix a gives an example; http://links.lww.com/eDe/B39). these considerations suggest methodological limitations in contrast-based methods for estimating population-averaged absolute risks.
When performing a network meta-analysis, selecting appropriate treatments for the systematic review is crucial, as this will influence the validity and generalizability of both the direct and indirect evidence summarized in the analysis. However, no guidelines exist for treatment selection. Because the control treatment may not be defined consistently across trials, some have suggested excluding such control treatments from a network meta-analysis 9-11 , but others have argued that having no comparison between an active intervention and placebo is problematic [12] [13] [14] . Moreover, the treatments of interest may differ in different countries, and may vary over time due to introduction of new drugs 15 . therefore, the treatment arms included in a network meta-analysis usually consist of a subset of a more extensive network. Using a contrast-based network meta-analysis 1,2 , Mills et al. 16 examined the sensitivity of estimated effect sizes such as Or to removal of certain treatments. they concluded that excluding a treatment sometimes has substantial influence on estimated effect sizes. consequently, selection of treatment arms should be carefully considered when applying network meta-analysis.
this article examines the sensitivity to treatment exclusion of an alternative approach to network meta-analysis, namely the arm-based approach, recently developed from the perspective of missing data analysis 17 . the detailed model is briefly reviewed in eappendix B (http://links.lww.com/eDe/B39). this model assumes (1) each study is independently chosen from a conceptual urn containing a large number of studies, and thus we can assign a joint distribution on the arm parameters independently across different studies; (2) each study hypothetically compares all treatments, many of which are missing at random. the armbased model does not estimate the population-averaged absolute risk of each arm independently; instead, it respects the study randomization by accounting for the correlations between treatments within each study, which allows for "borrowing information" across treatment arms. this point is illustrated by an example in eappendix a (http://links.lww.com/eDe/B39), in which absolute risk estimates from the arm-based model differ from estimates from a simple logit random effects model using only studies with a specific treatment arm. in addition, simulation results and real data analyses have shown that in some cases the effect size estimates given by this arm-based method are less biased than those given by the contrast-based model 17 .
Besides reporting changes due to treatment exclusion in the population-averaged absolute risk estimates from the arm-based model, we compare changes in relative effects (i.e., log Or change) with those obtained from the contrast-based model. in this regard, the arm-and contrast-based methods have a key difference: if a study only has two treatment arms and one of these arms is omitted from the network meta-analysis, a contrast-based analysis must omit the entire study, while an arm-based analysis can retain the single remaining arm. note that single-arm studies do contribute information to estimation of relative effects from the perspective of missing data analysis, which is somewhat counter-intuitive. to give a simple illustration, consider paired bivariate normally distributed random variables X and Y with parameters (µ µ σ σ ρ
), e.g., the probit-transformed absolute risks in the arm-based 
STATISTICAL ANALYSIS METHODS

Dataset Selection
We reviewed 40 network meta-analyses studied by Veroniki et al. 18 and selected 14 networks containing 567 rcts with a total of 389,361 participants. Our selection criteria were that every treatment in the network should be evaluated in at least three studies; otherwise, the networks are poorly connected at that treatment node. We denote the 14 networks as ara et al. (2009), 19 Ballesteros (2005) , 20 29 . tables 1 and 2 list their characteristics including the outcomes, the investigated treatments with their weighted node degrees, and the total number of studies, participants, and events. For each node (treatment) in a network, the weighted degree is defined as the sum of weights on all edges incident to that node. in a network meta-analysis, the edge weight equals the number of pairwise comparisons between two treatments, so the weighted degree represents the frequency with which a particular treatment is investigated in all of the network's studies. the node with the greatest weighted degree can be considered the most well connected. the network plots for the 14 datasets are shown in eFigure 1 (http://links.lww.com/eDe/B39). the 14 network datasets. the details about these models are given in eappendix B (http://links.lww.com/eDe/B39). We used Markov chain Monte carlo to compute posteriors for the effect sizes of interest, implemented using JagS 30 via the r 31 package "rjags" 35 .
analyses with a treatment removed were performed as follows. Suppose a network includes K treatments. We first applied both the arm-and contrast-based models to the complete network dataset (the full network) to estimate log Ors comparing each pair from the K treatments; we also estimated the population-averaged treatment-specific absolute risks using the arm-based model. next, for each treatment, we excluded it from the network and applied the analyses to the remaining dataset (the reduced network) consisting of K −1 treatments. the key difference between the arm-and contrastbased models becomes pertinent at this point. if a treatment 19 adverse event leading to drug discontinuation 11 5 atorvastatin 80 mg/day (atO 80) [9] ; simvastatin 40 mg/day (SiM 40) [8] ; simvastatin 80 mg/day (SiM 80) [7] ; rosuvastatin 40 mg/day (rOS 40) [5] ; placebo [3] Ballesteros (2005) 20 efficacy of antidepressants in dysthymia 9 4 Placebo [12] ; tricyclic antidepressant (tca) [8] ; monoamine oxidase inhibitor (MaOi) [5] ; selective serotonin reuptake inhibitor (SSri) [5] Bucher et al. (1997) 21 number of pneumocystis carinii pneumonia 18 4 aerosolized pentamidine (aP) [14] ; trimethoprim-sulphamethoxazole (tMP-SMX) [13] ; dapsone/pyrimethamine (D/P) [5] ; dapsone (D) [4] cipriani et al. (2009) 11 Unipolar major depression 111 12 Fluoxetine (FlU) [54]; paroxetine (Par) [32]; sertraline (Ser) [28] ; venlafaxine (Ven) [27] ; escitalopram (eSc) [17] ; citalopram (cit) [14] ; mirtazapine (Mir) [13] ; bupropion (BUP) [12] ; fluvoxamine (FVX) [11] ; duloxetine (DUl) [8] ; reboxetine (reB) [8] ; milnacipran (Mil) [ 22 Smoking abstinence 61 5 Placebo [64]; transdermal nicotine (tn) [23] ; vicotine gum (ng) [20] ; bupropion (BUP) [18] ; varenicline (Var) [9] elliott and Meyer (2007) 23 the proportion of patients who developed diabetes 22 6 β blocker (BB) [12] ; calcium-channel blocker (ccB) [12] ; angiotensinconverting enzyme inhibitor (acei) [11] ; placebo [10] ; thiazide diuretic (tD) [10] ; angiotensin-receptor blocker (arB) [5] lu and ades (2006) 3 Smoking cessation 24 4 individual counselling (ic) [21] ; no contact [20] ; group counselling (gc) [8] ; self-help [7] lu and ades (2009) 4 gastroesophageal reflux disease 40 6 H 2 receptor antagonist (H2ra) [34] ; proton pump inhibitor (PPi) [17] ; placebo [14] ; PPi double dose (PPi-D) [13] ; prokinetic agent (Pa) [6] ; H2ra double dose (H2ra-D) [ 24 Patients' dissatisfaction 20 4 "First generation" endometrial destruction techniques (Fg) [17] ; "second generation" endometrial destruction techniques (Sg) [14] ; hysterectomy (HYSt) [5] ; mirena (Mir) [ [26] ; lidocaine (mg) given before the injection of propofol (liDb) [19] ; no treatment (no trt) [19] ; opioids (OPi) [19] ; lidocaine (mg) with tourniquet (liD + tOU) [13] ; temperature (teM) [13] ; metoclopramide (Met) [ [33] ; inhaled corticosteroids (ic) [24] ; combined treatment with a long-acting beta-agonist and an inhaled corticosteroid (ct) [20] ; long-acting anticholinergics (ac) [11] thijs et al. (2008) 28 efficacy of antiplatelet 23 5 aspirin (aSa) [22] ; placebo [16] ; aspirin and dipyridamole (aSa + DP) [10] ; thienopyridines (ticlopidin or clopidogrel, tHi) [7] ; tHi + aSa [ [16] ; medical therapy (Mt) [13] was removed from a network, then for any two-arm studies that included that treatment, only one treatment arm remained. For an analysis using the arm-based model, we could keep the single-arm studies as they still contribute to the likelihood function from the perspective of an analysis with missing data. However, for an analysis using the contrast-based model, because it uses information about contrasts, the single remaining arm no longer provides any information for estimation in the reduced network, so the whole two-arm study must be deleted if one of the treatments is excluded. We retained multiarm studiesthose comparing more than two treatments-that included the removed treatment for analyses under both the arm-and contrast-based models. For the present study, we did not consider any exclusion that creates a disconnected or poorly connected network, i.e., that resulted in at least one treatment in a network being evaluated in fewer than three studies. table 2's "ineligible treatment removal" column shows treatment exclusions that produce such ineligible reduced networks under analyses with the arm-and contrast-based models. When comparing the arm-and contrast-based models, we only considered treatment removals that were eligible under both models. an example of which treatments were considered for exclusion is given in eappendix D (http://links.lww.com/eDe/B39).
Fold Changes of Estimated Absolute Risks in the Arm-based Model
For analysis using the arm-based model, we used fold changes of estimated population-averaged treatment-specific absolute risks to assess the impact of the treatment exclusion. assume that the population-averaged absolute risk for a particular treatment is estimated as π f using the full network and π r using the reduced network. then, the fold change for this treatment-specific absolute risk is defined as the maximum of ˆ/π π f r and ˆ/π π r f . thus, the fold change is never less than 1. Mills et al. 16 judged that a relative change not exceeding 1.03-fold is minor, while a change greater than 1.10-fold is large, and over 1.20-fold is substantial, although such categorization is subjective and may need to be adapted to specific situations.
Comparison Between Arm-and Contrast-based Methods
Without either external data or a separate model to estimate a reference treatment's absolute risk, the contrastbased method can only estimate Ors or their logarithms 8, 15, 17 . We focused on the changes in log Or (lOr) when comparing the arm-and contrast-based methods according to their sensitivity to treatment exclusion in the 14 networks. For each network and treatment exclusion, we applied both models to the full and reduced networks. then we calculated the lOr change (lOrc) as the difference between the lOr estimates using the full and reduced networks: LORC LOR LOR 29 26,521 821 0.031 124 22 BMS BMS 13 (13) c 52 (43) c a naïve absolute risk is calculated as the ratio of the total no. of events compared with the total no. of participants. b Weighted degree of a node (treatment) is the sum of weights (the number of pairwise comparisons between two treatments) on all edges incident to that node. c in each of these three networks, one particular treatment is not removed to remain network connectivity; the numbers in parentheses are given without accounting for these treatments. rather than their absolute values. to preserve any correlation structure between treatments in a network, when testing the difference between the arm-and contrast-based methods, we used bootstrap resampling 36 at the network level (using 10,000 bootstrap samples); that is, each bootstrap sample consisted of fourteen resampled networks, drawn with replacement from the original fourteen networks. Based on the bootstrap samples, we calculated 95% confidence intervals (cis) and P values for each model's mean absolute lOr change and their difference.
Because LORC LORC
RESULTS
Fold Changes of Estimated Populationaveraged Absolute Risks by the Arm-based Model
For the arm-based model, table 3 (1) removing treatments with larger weighted degree tends to cause larger fold changes, while the most affected treatment tends to have small weighted degree. in 6/14 networks, the maximal fold change is caused by the removal of treatment with the largest weighted degree; in 7/14 networks, the most affected treatment has the smallest weighted degree. (2) including more studies and increasing network connectivity may help to reduce the impact of treatment We should note that the factors above are not sufficient or necessary conditions when judging whether a network is robust to treatment exclusion. For example, Ballesteros (2005) 20 has only nine studies, but its average and maximal fold changes are smallest among the 14 networks. the changes may be small in this network because it has a high naïve absolute risk. =0, the lOr changes between treatments i and j appear symmetrically in both the scatterplot and the empirical cumulative distribution function graph. in addition, as each symmetric pair has the same absolute lOr change, we may only keep one value when we statistically test the difference between the arm-and contrast-based models. (the resulting P value remains the same if we include both values, as we use a nonparametric bootstrap resampling technique at the network level.) let µ AB and µ CB denote the true mean absolute lOr change (i.e., the expected value of LORC ij k − ( ) across all treatment exclusions in all networks) under the arm-and contrast-based models, respectively. Based on 10,000 bootstrap samples, µ AB is estimated as 0 020
Comparing the Arm-and Contrast-based Models
. with 95% ci 0 015 0 031 . , .
( ) ,
and µ CB is estimated as 0 047 . with 95% ci 0 029 0 100 . , .
− is estimated as 0 028 . with 95% ci 0 011 0 071 . , .
( ) .
therefore, the absolute change under the contrast-based model is larger than the change under the arm-based model, which suggests that the arm-based model is more robust than the contrast-based model to treatment exclusion. to see whether the smaller average absolute lOr change caused by the arm-based model is due to the additional information it uses (i.e., the retained single-arm studies), we applied the arm-based model to the same reduced networks that were used by the contrast-based model, in which singlearm studies were excluded. the Figure' s lower panels show the resulting lOr changes: the scatterplot and empirical cumulative distribution function graph suggest that the armand contrast-based models perform nearly the same when they use the same information. let µ AB denote the true mean absolute lOr change when applying the arm-based model to the data used by the contrast-based model. Using the same bootstrap approach as above, the 95% ci for µ AB . is 0 044 0 089 . , . . these findings indicate that single-arm studies-which the arm-based model can use-provide valuable information.
the above conclusions are based on using posterior means as Bayesian point estimates. We also considered posterior medians as point estimates, with results similar to those presented here.
DISCUSSION
this article examined the sensitivity of arm-based network meta-analysis to treatment exclusion, and compared that to the sensitivity of the contrast-based approach. For the arm-based model, we investigated the fold changes of estimated population-averaged absolute risks and found that the arm-based model is fairly robust for most networks. Because the changes of estimated populationaveraged absolute risks were mostly less than 1.05-fold, relative effect sizes based on the marginal absolute risks, such as the Or or relative risk, would also have small changes. although in general the changes were minor, removing specific treatments can be influential, as in, e.g., trikalinos et al. (2009) 29 . an influential treatment is typically investigated in many studies 16 , while infrequently studied treatments are most likely to be affected by exclusion of other treatments to which they were compared. this suggests that when performing a network meta-analysis, researchers should be cautious if they only want to assess new treatments or if they want to exclude placebo arms or well-established treatments 16 .
When we compared log Or changes, the arm-based model generally outperformed the contrast-based model. Using bootstrap resampling, the difference between the arm-and contrastbased models was statistically significant when single-arm studies were included in analyses using the arm-based model. However, when we dropped single-arm studies from reduced networks, the arm-based model performed almost the same as the contrastbased model. this implies that the arm-based model's greater robustness arises mainly from retaining single-arm studies. Some traditional pairwise meta-analyses have considered incorporating single-arm studies [34] [35] [36] [37] ; when single-arm studies are available for network meta-analysis, the arm-based model can be an attractive alternative approach.
One might wonder why the arm-and contrast-based models did not give identical results when the arm-based model was restricted by excluding single-arm studies in "comparing the arm-and contrast-based Models." the reason is that the two models involve different random-effect assumptions. Specifically, Shuster et al. 38 described two types of assumptions about random effects in meta-analysis. the first type of random effects, called "studies at random," assumes that the studies are independently chosen from a conceptual urn containing a large number of studies. the second type assumes that the relative effects in each study are randomly drawn from a conceptual urn while the studies are fixed; this is called "effects at random," which makes assumptions over and above studies at random, namely that the distribution of the random relative effects is independent of the study design. arguably, the arm-based model requires studies at random, while the contrast-based model requires effects at random.
Our study has several limitations. First, we did not check evidence consistency in the investigated networks; detecting inconsistency in network meta-analysis is still an open question, which is partly discussed by lu and ades 3 . For the contrastbased model, this article assumes that the pairwise comparisons among any trio of treatments, say a, B, and c, are interrelated = − + , which is discussed in Salanti et al. 5 Here, φ represents the inconsistency between the direct evidence for treatment B versus c and the indirect evidence from pairwise comparisons of a versus B and a versus c. For the arm-based model, one may consider detecting inconsistency between two treatments by comparing their absolute risk differences in direct comparisons versus indirect comparisons 39 . a large discrepancy implies potential inconsistency between these two treatments. the second limitation of our study is that we used a selection criterion requiring each treatment to be studied in at least three studies, mainly due to the need for an adequate number of studies to estimate parameters for the distribution of random effects. the literature has no well-established criterion serving this purpose.
in conclusion, arm-based methods can be an attractive alternative when data from some single-arm studies are available. For example, if we are interested in comparing treatments a, B, and c in a network meta-analysis, "single-arm" study data on a can come from two-arm studies comparing a versus D or other treatments. Furthermore, although the arm-based model is generally more robust than the contrast-based model, for some network metaanalyses, the contrast-based methods seem to be more robust to some treatment exclusions. For example, the lOr changes under the arm-based model can be fairly large, while the corresponding changes under the contrast-based model can be nearly zero (Figure) . therefore, analysts are advised to consider both the arm-and contrast-based models for network meta-analysis, especially when making inference for a small or poorly connected network.
